ClinicalTrials.gg
CompletedNCT06087575Updated Feb 9, 2026

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

An interventional study of Supira System in Coronary Artery Disease, High-risk Percutaneous Coronary Intervention and Interventional Cardiology, sponsored by Supira Medical. Completed at 4 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Supira Medical · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,105 studies in Coronary Artery Disease with a site in United States — 101 open to participants now, 146 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Enrollment
668th of 746
15 · median 107
Started
2024
with 35 others
No phase
353 of 1,105
43 open now
Registered
1,013th of 1,105
by date

Among the 1,105 studies in Coronary Artery Disease with a site in United States, this one is the 668th largest by enrollment of the 746 interventional ones that give a count, is one of 36 that started in 2024, is one of 353 with no phase, and was the 1,013th registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

101 of the 1,105 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,105 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. The clinical data may be used to support subsequent regulatory applications and further evaluation of the Supira System.

Read the detailed description

The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent HRPCI performed in hemodynamically stable patients with severe coronary artery disease when a heart team, including a cardiac surgeon, has determined HRPCI is the appropriate therapeutic option.

03

Conditions studied

  • Coronary Artery Disease
  • High-risk Percutaneous Coronary Intervention
  • Interventional Cardiology

Keywords

  • left ventricular assist device (LVAD)
  • peripheral mechanical circulatory support (MCS)
  • Supira System
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects will be eligible for inclusion in this study if all of the following criteria apply:

  1. Age ≥18 and ≤90 years
  2. Subject is hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is needed, as determined by the institutional heart team
  3. granted by the patient or legally authorized representative

Subjects who meet any one of the following criteria will be excluded from study participation:

  1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure

    a. Note: Cardiogenic shock is defined as: systemic hypotension (systolic blood pressure (BP) \<90 mmHg or the need for inotropes/pressors to maintain a systolic BP >90 mmHg) plus one of the following: any requirement for inotropes/pressors prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion or use of intra-aortic balloon pump (IABP), or any other circulatory support device.

  2. Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
  3. Evidence of left ventricular thrombus as assessed by Transthoracic Echocardiogram (TTE)
  4. Aortic valvular disease or regurgitation categorized as moderate or greater (≥2+ on a 4-grade scale as assessed on TTE)
  5. Aortic stenosis categorized as moderate or greater (gradient >20 mmHg or valve area \<1.5 cm\^2 as assessed on TTE)
  6. Previous aortic valve replacement or reconstruction
  7. Ascending or descending aortic dissection or aortic aneurysm >4.5 cm
  8. Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the device
  9. Presence of decompensated liver disease; severe liver dysfunction (Child class C)
  10. Ongoing renal replacement therapy with dialysis
  11. Infection of the proposed procedural access site or systemic active infection requiring ongoing antibiotic therapy
  12. Heparin-induced thrombocytopenia, current or any prior occurrences
  13. Known to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
  14. Known or suspected coagulopathy or abnormal coagulation parameters (defined as count ≤ 100,000/mm³ or spontaneous (INR) ≥1.5 or known fibrinogen ≤1.5 g/L)
  15. Any condition or scheduled surgery that will require discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
  16. Planned coronary intervention within 30 days post index procedure
  17. Breastfeeding or pregnant
  18. Currently participating in active follow-up phase of another clinical study of an investigational drug or device
  19. Active COVID-related infection or prior COVID-19 diagnosis with sequelae that could confound endpoint assessments
  20. Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
  21. Considered to be part of a vulnerable population (defined as individuals with mental disability, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Supira System

    Ventricular support indicated for use during elective or urgent high-risk percutaneous coronary interventions.

    Device: Supira System

Interventions

  • DeviceSupira System

    The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist device (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a HRPCI procedure. The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.

06

What researchers measure

Primary outcomes

  1. Feasibility: Successful initiation and maintenance of hemodynamic support

    Successful initiation and maintenance of hemodynamic support without severe hypotension throughout the index procedure. Sustained hypotension is defined as sustained mean arterial pressure (MAP) \< 60 mmHg requiring inotropic/pressor medications or alternative mechanical circulatory support.

    Time frame: From device delivery through removal (up to 4 hours)

  2. Safety: Rate of composite major device-related adverse events (MDRAEs), from device insertion through device removal (inclusive of Supira procedure-related SAEs).

    MDRAEs are defined as any serious adverse events that are adjudicated by the Clinical Events Committee (CEC) as definitely or probably related to the Supira System.

    Time frame: From device delivery through device removal (up to 4 hours)

Secondary outcomes

  1. Technical Success

    Rate of technical success, defined as completion of the entire Supira System procedure, including delivery, operation without device malfunction, and successful removal of the Catheter

    Time frame: From device delivery through device removal (up to 4 hours)

  2. Procedural Success

    Rate of procedural success, defined as the rate of technical success without procedural SAEs.

    Time frame: From device delivery through device removal (up to 4 hours)

  3. Rate of composite MDRAEs from device removal through hospital discharge or 72 hours post-procedure, whichever occurs first.

    Time frame: From device removal through hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.

  4. Rate of composite MDRAEs from hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.

    Time frame: From hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.

  5. Rate of composite MDRAEs from 30 days to 90 days post device removal.

    Time frame: From 30 days to 90 days post device removal.

07

Study locations

4 sites
  • University of California Davis (UC Davis) Medical Center
    Sacramento, California 95817, United States
  • Piedmont Heart Institute Cardiovascular Research
    Atlanta, Georgia 30309, United States
  • Mount Sinai
    New York, New York 10029, United States
  • Montefiore Medical Center Cardiology Research
    The Bronx, New York 10467, United States
08

References and documents

Publications

  • Kandzari DE, Mignatti A, Kini A, Wong G, Singh G, Latib A, Costa R, Campos CM, Abizaid A. Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study. Circ Cardiovasc Interv. 2026 May 5:e016010. doi: 10.1161/CIRCINTERVENTIONS.125.016010. Online ahead of print. PubMed 42083862 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Feb 2025, 4 months.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 4 months is below that.

Counting every sponsor, half of 932 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 18, 2023
StartActual
Oct 4, 2024
Primary completionActual
Feb 25, 2025
CompletionActual
Apr 17, 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06087575
Lead sponsor
Supira Medical
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Oct 4, 2024
Primary completion
Feb 25, 2025
Completion
Apr 17, 2025
Last update
Feb 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion